Cargando…
Refractory primary immune thrombocytopenia (ITP): current clinical challenges and therapeutic perspectives
Chronic primary immune thrombocytopenia (ITP) can today benefit from multiple therapeutic approaches with proven clinical efficacy, including rituximab, thrombopoietin receptor agonists (TPO-RA), and splenectomy. However, some ITP patients are unresponsive to multiple lines of therapy with prolonged...
Autores principales: | Vianelli, Nicola, Auteri, Giuseppe, Buccisano, Francesco, Carrai, Valentina, Baldacci, Erminia, Clissa, Cristina, Bartoletti, Daniela, Giuffrida, Gaetano, Magro, Domenico, Rivolti, Elena, Esposito, Daniela, Podda, Gian Marco, Palandri, Francesca |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8867457/ https://www.ncbi.nlm.nih.gov/pubmed/35201417 http://dx.doi.org/10.1007/s00277-022-04786-y |
Ejemplares similares
-
Sustained response off therapy after fostamatinib: A chronic refractory ITP case report
por: Auteri, Giuseppe, et al.
Publicado: (2023) -
Severe Immune Thrombocytopenia (ITP) Following SARS-CoV-2 mRNA Vaccine in a Girl on Immunosuppressive Treatment and in Prolonged Stable Phase of ITP
por: Bianchi, Simona, et al.
Publicado: (2022) -
Risk of Immune Thrombocytopenia Relapse and Onset Related to Sars-Cov-2 Infection and Vaccination
por: Auteri, Giuseppe, et al.
Publicado: (2022) -
Immune Thrombocytopenia Onset and Relapse During the COVID-19 Pandemic. A Monocenter Study
por: Auteri, Giuseppe, et al.
Publicado: (2023) -
Second-line administration of thrombopoietin receptor agonists in immune thrombocytopenia: Italian Delphi-based consensus recommendations
por: Carpenedo, Monica, et al.
Publicado: (2021)